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Abstract 
Adverse drug reactions (ADRs) represent a serious worldwide public health problem. Current post-
marketing ADR detection approaches largely rely on spontaneous reports filed by various healthcare 
professionals such as physicians, pharmacists et.al.. Underreporting is a serious deficiency of these 
methods - the actually reported adverse events represent less than 10% of all cases. Studies show that 
two important reasons that cause the underreporting are: 1) healthcare professionals are unaware of 
encountered ADRs, especially for those unusual ADRs; 2) they are too busy to voluntarily report ADRs 
since it takes a lot of time to fill out the reporting forms. This paper addresses these two issues by 
developing a multi-agent ADR reporting system. The system 1) helps healthcare professionals detect 
the potential causal relationship between a drug and an ADR by analyzing patients’ electronic records 
via both case-based analysis and statistical data mining approach; 2) allows healthcare professionals 
to add new rules to signal potential ADRs based on their medical expertise; 3) makes the reporting 
much easier by automatically linking the patients’ electronic data with the reporting form. A 
functioning prototype of the system has been developed. The proposed data analysis approaches as 
well as the performance of the system have been tested. The results indicate that this system has a 
great potential to improve the spontaneous reporting rate of suspected adverse drug reactions. 
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Introduction 
Thousands of drugs are currently available on the U.S. market. These drugs can occasionally 
cause adverse drug reactions (ADRs) in patients. An ADR is defined by the World Health 
Organization (WHO) as “an effect which is noxious and unintended, and which occurs at doses 
used in man for either prophylaxis, or diagnosis, or therapy.” [1]. ADRs could worsen the 
patient’s medical problems, place patients in life-threatening situations, lead to increased health 
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care costs, and extend patients’ length of stay in hospitals. For example, a recent study of ADRs 
in U.S. hospitals [2] indicates that about 2 million hospitalized patients per year experience 
serious ADRs and approximately 100,000 die from ADRs, which rank the fifth in leading causes 
of death as well as being one of the more frequent causes of hospitalization. In addition, patients 
experiencing an ADR while hospitalized have a substantially increased risk of death 
(approximately 20%) and incur significantly higher costs for hospitalization and drug treatments 
(estimated at $516 million in total costs and $37 million in additional drug costs for Medicare 
patients alone [2]). 
Even though premarketing clinical trials are required for all new drugs before they are approved 
for marketing, these trials are necessarily limited in size and duration and are not capable of 
detecting relatively infrequently occurring adverse reactions caused by normal use of drugs. In 
general, if the occurrence rate of a potential ADR is less than 0.1%, it cannot be recognized in 
randomized and controlled clinical trials due to limitations in trial size [3]. As an example, 
bromfenac (marketed as Duract) was a nonsteroidal antiinflammatory (NSAID) agent that was 
removed by the Food and Drug Administration (FDA) from the market in 1998, less than 1 year 
after it was introduced, because it caused liver injury in 1 in approximately 20,000 patients 
taking the drug for longer than 10 days [4]. This type of rare and delayed drug reaction is very 
difficult to detect during preapproval clinical trials since most new drugs are approved after an 
average of only 1,500 patient exposures. 
Drug safety depends heavily on postmarketing surveillance - the systematic detection and 
evaluation of medicines once they have been marketed [3]. Current postmarketing methods 
largely rely on voluntary, spontaneous reports of suspected ADRs to be filed by various 
healthcare professionals such as physicians, pharmacists, and others. To ensure quality of patient 
care, many healthcare facilities (e.g., hospitals) have a drug safety office which collects 
spontaneous ADR reports and monitors the safety of drugs, particularly recently marketed drugs. 
At the national level, many countries have their own spontaneous reporting systems. For 
example, the United States has an ADR reporting system called MedWatch, which is managed 
by the FDA. Internationally, the World Health Organization (WHO) also maintains a similar 
reporting system that collects individual case safety reports from healthcare providers in member 
countries of the WHO Program. 
Because ADR reports are filed at the discretion of the users in the reporting system, there is gross 
underreporting [5-7]. Hazell and Shakir examined 37 studies from 12 countries and found that 
the median underreporting rate across these studies was 94% (interquartile range 82-98%) [6]. 
Because of underreporting, long delays occur before a sufficient number of suspect cases 
(signals) are accumulated to raise concern among clinicians and regulators. Consequently, the 
current post-marketing surveillance approach may require years to identify and withdraw 
problematic drugs from the market [8,9], and result in unnecessary mortality, morbidity, and cost 
of healthcare. 
Studies have shown that lack of time and uncertainty of reactions being caused by drugs are two 
major reasons that hinder reporting [10-12]. As indicated by the study of [10], more than 35% of 
medical practitioners have the opinion that reporting of ADRs takes too much time, and it is too 
bureaucratic. For instance, the FDA’s reporting form has four sections: patient information, 
adverse event, suspect medication(s), and reporter information. For each section, a lot of specific 
details are requested. For example, the adverse event section requests outcomes attributed to 
 
  
A Multi-Agent System for Reporting Suspected Adverse Drug Reactions 
 
3 
Online Journal of Public Health Informatics * ISSN 1947-2579 * http://ojphi.org * 6(3):e193, 2014 
OJPHI 
adverse event, date of event, date of report, description of event, relevant tests/laboratory data 
including dates, and other relevant history including preexisting medical conditions (e.g. 
allergies, race, pregnancy, smoking and alcohol use, hepatic/renal dysfunction, et.al.). Finding 
these details and putting them in a reporting form are both tedious and time-consuming. 
Uncertainty as to whether the reaction is caused by a drug is another important factor for 
underreporting [10]. Elucidating causal relationships between a drug and an outcome of interest 
is often clouded by broad boundaries of uncertainty. Reasons for uncertainty include (i) multiple 
conditions may result in similar outcomes (e.g., a possible ADR); (ii) a drug may be essential for 
producing an outcome or condition of interest; however, it is not a sufficient cause in and of 
itself. That is, there may be other circumstances such as genetics or other underlying conditions 
that participate in concert with the drug to produce the adverse outcome. 
Intelligent agents provide a promising approach to ameliorating the underreporting problem 
because they can act on behalf of human users to find and filter information, automate complex 
tasks, and collaborate with other software agents to assist complex decision-making. Even 
though intelligent agents have been used for different purposes, they usually share some common 
characteristics such as autonomy, collaboration, delegation, and communication. A multi-agent 
system may be defined as “a collection of autonomous agents that communicate between 
themselves to coordinate their activities in order to be able to solve collectively a problem that 
could not be tackled by any agent individually” [13]. 
The multi-agent technology provides a new paradigm for developing artificial intelligence 
applications in a variety of fields. In the health care domain, exemplary applications include the 
AADCare (agent architecture for distributed medical care) system for integrating the patient 
management processes [14], the Organ Transplant Management system for the management of 
organ and tissue transplants among different medical centers [15], the internal hospital tasks 
management systems for monitoring the application of medical protocols [16], the ADR-Monitor 
system for monitoring potential ADRs of interest using electronic patient records [17], and the 
multi-agent system used for finding similar patients [18]. Up to date, the number of biomedical 
applications is still very limited. 
In this paper, we develop a functioning prototype of an agent-based spontaneous ADR reporting 
system. The system provides both case-based analysis and statistical data mining approach to 
help healthcare professionals establish the causal relationship between a drug and a potential 
ADR. In addition, the system has a rule-adding framework that allows healthcare professionals 
to add new rules to signal potential ADRs based on their medical expertise. Moreover, once a 
healthcare professional decides to file an ADR report, his/her assistant agent will retrieve the 
required data from related electronic health databases and automatically fill a significant portion 
of the reporting form. As a result, filing a report would become much easier and takes 
significantly less time than existing methods. 
Methods 
Multi-Agent System Architecture 
Our agent system architecture designed for a healthcare organization is shown in Figure 1. Note 
that a healthcare organization can be a hospital, a medical center, a sizable clinic, or any other 
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health organizations in which people would like to file ADR reports. There are four types of 
agents: assistant agent, data mining agent, management agent, and data collection and 
monitoring agent. The first three types of intelligent agents are accessible by any computer 
connected to the Internet through web pages. All these agents can communicate with each other 
through agent communication languages. The databases at a healthcare organization contain 
detailed information of its patients. The data are important since they provide, among other 
information, direct or indirect evidence of the clinical state, and comorbid conditions. 
 
Figure 1: Multi-agent system architecture 
Physicians or other healthcare professionals have their own intelligent assistant agents, which 
would help them effectively file ADR reports. First, each assistant agent can communicate with 
various data collection and monitoring agents and obtain the electronic data of the involved 
patient for a particular ADR. More importantly, the agent is powered by a rule-based algorithm 
which can assess the degree of causal association between a drug and a potential ADR based on 
the retrieved patient data related to a particular patient. Second, a healthcare professional can add 
new rules (through his/her assistant agent) to signal potential ADRs based on his/her expertise 
and experience in a particular class of drugs or ADRs. Third, an assistant agent can contact the 
data mining agent to get high-level statistical information regarding the strength of the 
association of a drug-ADR pair. Fourth, if a healthcare professional decides to file an ADR 
report, his/her agent would automatically feed the available data to the reporting form. More 
details regarding the rule-based algorithm, the data mining method, the rule-adding framework, 
and the auto-filling process will be described in the next section. 
The data mining agent is maintained by a safety officer/manager who has background in 
epidemiology or biostatistics. The agent collects statistical data through data collection and 
monitoring agents and calculates the value of an adopted interestingness measure for suspected 
drug-ADR signal pairs. The value of the measure indicates the strength of the association of a 
drug-ADR pair from a statistical perspective. The agent keeps a list of signal pairs and 
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periodically updates the measure’s value for all pairs. If a healthcare professional wants to look 
at the statistical strength of a particular signal pair, the data mining agent would search its list 
and send the information to his/her assistant agent. 
The management agent provides agent management, a white-page service through which an 
agent can register and discover other agents, and a yellow-page service through which an agent 
can publish and search for “services.” An agent is allowed to subscribe services. Whenever a 
service registration or modification is made, the agent will be notified. 
The data collection and monitoring agents convert information requests from other agents into 
appropriate SQL (Structured Query Language) statements and retrieve the data from various 
databases. Moreover, they help other agents track further development of the suspected patient 
cases. For example, a physician may be interested in what happens to the patients after the 
suspected drug is discontinued. In general, the physicians and other healthcare professionals 
could more easily determine the causal relationship between a potential ADR and a drug by 
monitoring the related cues. 
System Design and Functionalities 
In this section, we present the detailed system design and functionalities. Specifically, we discuss 
how the agent-based system assists healthcare professionals in submitting ADR reports, by 
providing both case-based and statistical decision support, by allowing healthcare professionals 
to add new rules for evaluating the potential causal association between a drug and an ADR, and 
by automatically filling out most of the reporting form using electronic health data. 
Decision Support 
To help healthcare professionals confirm potential ADRs, our reporting system provides two 
types of decision support. First, each assistant agent can utilize a rule-based algorithm to assess 
the degree of causal association between a drug and an ADR based on the electronic data of a 
single patient. Second, the data mining agent can also do a numerical analysis of the correlation 
between a drug and ADR using a data mining method. 
1) Single Patient Evaluation Using a Rule-Based Algorithm 
The physician and pharmacist in the project team developed a rule-based algorithm (Table 1) in 
order to evaluate the potential association between a drug and an ADR on the basis of a patient’s 
electronic data. The design of the algorithm was based on their own expertise and the literature 
research [19]. The algorithm poses a list of questions that indicate the correlation of a drug-ADR 
pair from different aspects. Each question has a set of answers, each with a score or “weight”. 
For instance, the answer to an example question “Is the patient 65 or older?” might be “Yes 
[+1]”, “No [-1]”, or “unknown [+0]”. The number in the bracket is a score assigned to the 
corresponding answer. One can see that each answer represents an IF-THEN rule. For instance, 
the answer “Yes [+1]” to the above question indicates “IF the patient is 65 or older, THEN the 
score of this question is +1 for the patient”. The score for a patient case is calculated by summing 
up the scores of each question. Depending on the total number of scores accrued, one of the four 
labels – “definite”, “probable”, “possible”, or “doubtful” - is assigned to the ADR. 
2) Statistical Association Analysis Using a Data Mining Method 
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Studies have shown that data mining techniques can be very helpful in analyzing the electronic 
health data and discovering potential ADRs [20-24]. However, mining the association between a 
drug and an ADR is not easy due to the large size of the data. Since electronic patient data are 
generally stored in relational databases, we developed a SQL-based association mining algorithm 
that can deal with large amount of data. The algorithm employs risk ratio to evaluate the strength 
of association between each drug-ADR pair given all the electronic data in a database. 
Risk ratio (RR) provides a measure of association between an exposure and the outcome of 
interest. In mathematical epidemiology, it is defined as a ratio of the probability of the event 
occurring in the exposed cohort versus a non-exposed cohort. Risk ratio is used widely in the 
statistical analysis of binary outcomes where the outcome of interest has relatively low 
probability. The magnitude of risk ratio may vary from 0 to infinity. When the risk ratio is over 
1.0, the incidence of the outcome is greater in the exposed cohort than the unexposed cohort. In 
our study, this method is used to investigate the potential association between the drug of interest 
(exposure) and a reaction (outcome). Specifically, it is employed to compare the risk of 
developing an ADR in people receiving a drug as compared to the people who are not receiving 
the drug. Its calculation is based on a 2x2 contingency table as shown in Table 2. The formula is 
given below:  
 
Table 1: Rule-based algorithm 
When did the adverse drug reaction occur? 
• Prior to Drug Administration [-1] 
• Unknown [0] 
• Less than two weeks later [+3] 
• Less than one month later [+2] 
• Less than six months later [+1] 
• More than six months later [0] 
Is the patient 65 or older? 
• Yes [+1] 
• Unknown [0] 
• No [-1] 
Did the reaction stop if the drug was no longer 
administered? 
• Yes, within one week [+2] 
• Yes, within one month [+1] 
• Yes, more than one month later [0] 
• No [0] 
If the patient was given the drug again, did the 
reaction re-occur? 
• Yes, within one month [+2] 
• Yes, more than one month later [0] 
• No [-3] 
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The total score calculated from the above questions 
defines the category of an ADR as follows: 
<= 1 [Doubtful] 
2 – 4 [Possible] 
5 – 8 [Likely] 
9 – 10 [Definite] 
However, the risk ratio value alone is insufficient to determine association since we must ask 
whether an estimate for the risk ratio is statistically significant. Can the estimate that is greater 
than 1.0 be attributed to chance, or is it sufficiently greater to require further scrutiny? For 
statistical inference in this study, we also calculate the Chi-Squared ( 2χ ) value as shown below: 
 
Where n represents the number of cells in the table and it is equal to 4. That is, the summation 
applies over all four cells of the 2x2 contingency table. Oi is the observed frequency and Ei is the 
expected (theoretical) frequency asserted by the null hypothesis. For example, O1 and E1 for the 
first cell should be calculated as 
 
 
Table 2: Two-by-two contingency table for reactions 
 Patients with drug of interest 




reaction of interest a b 
 
Patients with all 
other reactions c d 
 
For the remaining cells it takes the value contained in the cell (i.e. b, c, d) in turn. 
To confirm a drug-reaction signal pair, we also include another factor: the number of patients 
with the reaction of interest in the database (i.e., a in the Table 2). The reason is that, even a 
fairly small a can possibly produce a high risk ratio. But, in post-marketing surveillance, a signal 
pair generated by an interestingness measure is generally not considered as valid if only one or 
two patient cases contain the pair [25]. 
Considering the above three factors, we mark a drug-reaction pair as a signal when it satisfies: 1) 
2RR > , 2) 2 4χ > , and 3) 3a ≥ . Hence, the association mining task is to find all the drug-reaction 
pairs that satisfy the three criteria in a relational database. We use 𝐷(𝑑1,𝑑2, …𝑑𝑖 , …𝑑𝑚) to 
represent a list of all drugs in the pharmacy database. Similarly, 𝑅�𝑟1, 𝑟2, … 𝑟𝑗 , … 𝑟𝑛� is utilized to 
represent a list of all reactions (or medical conditions) covered by the patient medical record 
database. Each pair< 𝑑𝑖 , 𝑟𝑗 >forms a potential association 𝑑𝑖 → 𝑟𝑗whose RR value needs to be 
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computed based on the contingency table shown in Table 2. We assume that all the data needed 
to calculate the RR value are in three tables: Demography Table containing patient’s 
demographic information such as age, gender, weight, etc., Drug Table consisting of drug-related 
data such as drug name, dose, start date, etc., and Reaction Table containing reaction-related data 
such reaction name, start date, and so on. 
Our association mining algorithm is shown in Algorithm 1 where the same variables (i.e. a, b, c, 
and d) in Table 2 are used in the description of the algorithm. To compute RR based on Eq (1), 
four values need to be obtained; i.e., a, a+c, b, and b+d. Six getxxx() functions are utilized to get 
all drugs and reactions as well as all the information needed to compute the four values. The two 
functions getAllDrugs() and getAllReacs() retrieve all the distinctive drugs and reactions from 
Drug Table and Reaction Table, respectively (line 1 and 2). The function 
getTotalNumOfPatients() is used to obtain the total number of patients (line 3) from 
Demography Table. Note that each patient is uniquely identified by a patient identification (PID) 
number that represents the primary link field (primary key) between database tables. In addition, 
one or more drugs and reactions may appear in a single patient record. For each distinctive drug 
𝑑𝑖, the function getTotalNumOfPatientsOnDrug (𝑑𝑖) is used to obtain a+c (from the Drug Table) 
which represents the total number of patients who have taken the drug (line 5). Since the total 
number of patients is equal to a+c+b+d, b+d can be obtained by subtracting a and c from the 
total number of patients (line 6). Given a pair < 𝑑𝑖, 𝑟𝑗 >, the function 
getTotalNumOfPatientsOnDrug&Reac(𝑑𝑖,𝑟𝑗) is used to get a (line 8) based on both Drug Table 
and Reaction Table. The value of b is obtained by first getting the total number of patients on the 
reaction 𝑟𝑗 (which represents a+b) and then subtracting a from this number (line 9). After all the 
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The data mining agent maintains a list of drug-reaction pairs. For each pair, its RR, 2χ , and a are 
updated periodically (e.g. each week) under the help of data collection and monitoring agents. A 
pair is marked as a signal when it satisfies the criteria defined above. A higher risk ratio value 
indicates a stronger signal when the other two criteria are satisfied. If a healthcare professional 
wants to confirm a potential ADR before reporting it, his/her assistant agent can always contact 
the data mining agent and bring the above three values to him/her. 
Rule-adding Framework 
To make our multi-agent system more flexible and useful, a rule-adding framework is designed 
to allow healthcare professionals to adjust existing rules or adding new rules in the rule-based 
algorithm based on their knowledge of a particular class of drugs or ADRs. For example, a class 
of drugs frequently used in a particular medical domain (e.g., Psychiatry) may cause an ADR 
only after the drug toxins are accrued to a certain level after patients have taken the drug(s) for a 
long time. In such a case, healthcare professionals in the domain may want to adjust the scores 
assigned to each answer for the question “When did the adverse drug reaction occur?” in Table 
1. In addition, other factors (e.g., abnormal lab results) can indicate the occurrence of ADRs 
caused by a particular class of drugs. In these cases, new questions and rules can be added to the 
algorithm through the framework. 
Virtually any “question” that can be expressed in English and answered using information from a 
hospital database can be added to the framework. Healthcare professionals have the ability to 
select which signals would be used to indicate a potential ADR and add their medical expertise 
to our framework using their assistant agents. Any rule, whether a part of the rule-based 
algorithm or a custom rule added by a healthcare professional, is stored in a table in a database. 
Each rule consists of four parts: rule ID, descriptions, status, and code. The rule ID represents a 
unique identifier of a rule. The descriptions part provides specific descriptions of a rule in 
English language. The status (either active or non-active) of a rule indicates whether a rule is 
used when calculating a patient’s total score. The code portion is critical, as it formally describes 
what variable is evaluated, the upper or lower limit, and the score if the condition of a rule is 
satisfied. 
We developed a custom language to make up the code section of a rule. The custom language is 
translated into a SQL command that is then executed. Generally, the code follows this format: 
First of all, a database table name and a column name within that table are listed. Then an 
operator and a constant is listed, followed by a score. The table/value, the operator, and the 
constant combine to form the IF-condition of a rule. If the condition is answered “yes”, then an 
appropriate score is assigned to the rule. The code for an example question “Is the patient greater 
than 65 years old?” is expressed as “Patient Table|Age|>|65|1”, where the vertical bars (|) 
represent the delimiters of different components of the code. The “Patient Table” refers to a table 
in the hospital database from which data are retrieved and evaluated. The “Age” represents a 
column name in the “Patient Table”. The symbol “>” is an operator that represents “greater 
than”. The two numbers “65” and “1” represent the lower limit of “Age” and the score, 
respectively. Table 3 is a list of operators supported by the custom language. Note that users do 
not need to learn the custom language and manually create the code for each rule. An easy-to-use 
web interface is provided to allow users to select the patient table, column name and operator, 
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and enter the upper and/or lower limit and the score. The system then automatically generate the 
code based on the inputs. 
Table 3: List of operators in the custom language 
Operator Description 
< Less than 
<= Less than or equal to 
> Greater than 
>= Greater than or equal to 
= Equal to 
!= Not equal to 
Between Between two specified values 
Diff Difference between two values 
Auto-Filling 
Analysis of various ADR reporting forms indicates that the majority of information requested 
can be obtained from the healthcare organization’s electronic health databases. This includes 
patient demographics and disease history, reporter identification, and general information 
regarding medication. By developing a system that automatically retrieves the information and 
fills them in, we can reduce the amount of work required by the reporters. As a result, the 
professionals would become more willing to file an ADR report. 
We have implemented the auto-filling property using the FDA’s spontaneous reporting form. 
The user of our prototype system is provided with a web-based interface through which he/she 
can login the reporting system. After that, the user is taken to a new page and linked with his/her 
assistance agent. For a new user of the system, he/she needs to apply for an account and then a 
new unique assistant agent will be created for him/her by the system. Note that an agent keeps 
running in the background unless it is deleted. To report an ADR, the user enters two 
identification numbers which identify the patient and medication suspected (i.e., Patient_ID and 
Medication_ID). From there the assistant agent will retrieve all the information needed to fill out 
the FDA form except the Date of Event and a Description of the Event. This is a significant 
reduction in the amount of information the reporter is required to fill out. The system will then 
return to the user a form with all of the information filled out so that the user can review the form 
before submitting it. 
System Implementation 
The implementation of the ADR reporting system follows the Model-View-Controller (MVC) 
pattern as shown in Figure 2 [26]. The model consists of the intelligent agents of the system. The 
view defines the presentation layer of an application which consists of web pages in our system. 
The controller manages the flow of the system, and this work is done by servlets. A servlet is a 
small Java program that receives requests from Web clients, usually across the HyperText 
Transfer Protocol (HTTP). The requests can be forwarded to the model, which may trigger data-
based analysis. The analysis results will be returned to the servlet and then be forwarded to the 
view for presentation. The Data Store in Figure 2 represents the various electronic health 
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databases in our system. Since we use a couple of tools that are implemented in Java, we build 
the system using the Java programming language. 
 
Figure 2: Block diagram of MVC model 
Web-Based Interface 
We implemented our web interface using Apache Tomcat, an open source software 
implementation of the Java Servlet and JavaServer Pages (JSPs) technologies. Tomcat is used as 
both the web server and the servlet and JSP engine for our web-based interface. JSPs allow us to 
embed basic Java code in HTML pages, while servlets do the processing for the dynamic web 
pages of our system. NetBean was used as the development environment for developing the 
whole system including JSPs, servlets, intelligent agents, and interface to databases. 
Intelligent Agents 
Agent-related implementation issues include agent creation, communication, interoperability, 
and service registry. We found that the Java agent development environment (JADE [27]), one of 
the agent system development software packages, could readily handle them. We utilized it to 
implement these aspects of the intelligent agents in our reporting system. JADE is an integrated 
tool suite for constructing, managing, and testing intelligent software agents. It fully complies 
with the Foundation for Intelligent Physical Agents (FIPA) specifications and adopts FIPA ACL 
as agent communication language. The FIPA standards allow agents effectively interoperate with 
each other. JADE provides both white-page and yellow-page services for agent management. 
These features free us from many of the implementation details of developing and managing 
agents, and allow us to focus our time and energy on developing their behaviors and interactions. 
Implementation of Rule-adding Framework 
As explained earlier, each rule in the rule-based algorithm is formally represented by its code 
which will be automatically translated into a SQL statement. For example, the code for question 
“Is the patient greater than 65 years old?” is “Patient Table|Age|>|65|1”. It would be translated 
into a SQL statement “SELECT PID, Age FROM `Demography Table` WHERE Age>65”. The 
patient identifier (i.e., PID) is automatically added to the statement and it is known from the 
context. That is, when a healthcare professional intends to file an ADR report, he/she must 
identify the patient relevant to the report so that his/her assistant agent can analyze the patient’s 
records using the rule-based algorithm. This SQL query would return each row in the database 
that contains the desired patient’s id and an age value greater than 65. If a row was correctly 
returned, we know the patient is older than 65 years, so the appropriate score should be assigned. 
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We implemented web pages for the rule-adding framework through which users can edit existing 
rules or add new ones based on their medical expertise. 
Results 
Experiment Data 
To test our ADR reporting system, we created four relational MySQL databases (i.e., pharmacy 
database, administration database, laboratory database, and patient medical record database), 
each of which contains certain types of data. The creation of the databases were based on real 
data from the FDA’s Adverse Event Reporting System (AERS) and our past experience in 
working on real health datasets retrieved from the Veterans Affairs Medical Center in Detroit, 
Michigan. The AERS is a database that contains approximately 4.5 million ADR reports, with 
approximately 100,000 additional reports released each quarter. The AERS data is freely 
available in plaintext format on the FDA’s website. When importing the AERS raw data into our 
databases, we made some changes. For example, we standardized ages by converting from days, 
weeks, months, or decades into years. We also pruned out patients missing any data regarding 
drug name, or therapy start/end dates. As a result, we obtained 801,623 patient cases in our 
databases based on the AERS data released in the last two years. 
Experiment Results 
Using the above data, we tested the two decision-making strategies (i.e., case-based analysis 
using the rule-based algorithm and statistical analysis using RR) imbedded in our system, the 
scalability of the association mining algorithm as well as how indexes affect the performance of 
the algorithm. The experiments were done on a PC with a 3.4GHz Intel i7-3770 processor and 8 
GB of RAM, running Windows 7. 
We first examined the degrees of agreement between the causality categories (i.e., “Definite”, 
“Likely”, “Possible”, and “Doubtful”) assigned by the rule-based algorithm and those by an 
experienced physician. To do this, we randomly selected 100 patient cases, within each of which 
a distinctive drug-ADR pair was reported. According to the HIPAA (Health Insurance Portability 
and Accountability Act) privacy regulations, a healthcare professional can only access the data of 
his/her own patients. We assume that the selected patients are associated with a particular 
healthcare professional. These 100 patients were used to validate the assignment of causal link 
strengths by the proposed rule-based algorithm. Since our patient data were derived from FDA’s 
spontaneous reports, the reported drug and potential ADR are known for each patient case. The 
algorithm was used to identify and assign likelihoods of causal associations between the drug 
(cause) and ADR (effect) for the 100 patients. To provide preliminary validation for the capacity 
of the rule-based algorithm, the physician on our project team participated in the experiment. He 
was provided a general overview of the objectives of the study and was asked to review each of 
the 100 patient cases and make a judgment regarding the likelihood of a significant causal 
association between each drug-ADR pair. To make the following agreement assessment easier, 
both the rule-based algorithm and the physician assigned a numerical number between 1 and 4 
based on the strength of the perceived causality, where 4 means “definite causal relationship,” 3 
is “likely casual relationship,” 2 indicates “possible causal relationship,” and 1 stands for 
“doubtful causal relationship. 
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Because scoring of the causal association was based on ordinal data, we utilized the weighted 
Kappa statistic [28,29] to estimate the levels of agreement between the rule-based algorithm and 
the physician. The Kappa coefficient is an estimate of the agreement between two raters after 
chance agreement is controlled. Kappa scores range between 1 (complete agreement) and 0. 
Because there are no “absolute” interpretations of the Kappa coefficients, experts have offered 
opinions regarding interpretations of agreement. Landis and Koch [30] suggest that for values of 
Kappa greater than 0.75, there is excellent agreement. For values less than 0.4, there is poor 
agreement, and for values between 0.40 and 0.75, there is fair to good agreement. The calculated 
Kappa between the algorithm and the physician is 0.894. This coefficient suggest excellent 
agreement between the proposed algorithm and the physician. We computed the 95% confidence 
intervals using both the Asyptotic formula and the Jackknife method. The results of these two 
methods agreed to the second decimal as shown in Table 4. 
Table 4: 95% confidence intervals for weighted Kappa coefficients from Asymptotic formula 
and Jackknife method 





Physician vs. rule-based algorithm 0.894 (0.837, 0.952) (0.838, 0.954) 
We also examined the consistence between the case-based analysis using the rule-based 
algorithm and the statistical analysis using RR. For each drug-ADR pair in the 100 patients, its 
RR, 2χ  and a were calculated based on all the 801,623 patient cases. Whether a pair represents 
an ADR signal is determined by the criteria ( 2RR > ; 2 4χ > ; 3a ≥ ) established earlier. Table 5 
gives the number of drug-ADR pairs in each causality category based on the rule-based 
algorithm as well as how many pairs in each category represent ADR signals according to the 
statistical analysis criteria. One can see that, among the 100 drug-ADR pairs in the selected 
patients, 68 of them represent ADR signals that are confirmed by the statistical approach. In 
addition, if a pair exhibits a stronger causality according to the case-based analysis, it more likely 
represents a signal established by the statistical analysis. 
Table 5: The number of drug-ADR pairs in each causality category based on the rule-based 
algorithm as well as the number pairs (in each category) that represent ADR signals according to 
the statistical analysis criteria 
 “Definite” “Likely” “Possible” “Doubtful” Total 
Number of pairs in each 
category based on the rule-
based algorithm 
18 43 27 12 100 
Number of pairs that represent 
ADR signals according to the 
statistical analysis. 
17 34 15 2 68 
Percentage of pairs that 
represent ADR signals 94.4% 79.1% 55.6% 16.7% N/A 
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Since our association mining algorithm is SQL-based its performance can be greatly affected by 
database indexes. In addition, the number of database connections can also affect the 
performance of a SQL-based algorithm. To query data, one approach is to create a connection to 
the related database for each SQL statement and then close the connection after the query. 
Another approach is to create a single connection for each database that will be used by all the 
SQL statements in the algorithm. We tested how different combinations of these two factors (i.e., 
index and number of connections) affect the performance of our algorithm. The experiment data 
contains 5,281 drugs and 7,943 reactions. Since the execution time of the program without 
indexes is very long we randomly chose 100 drugs and 100 reactions for this experiment. That is, 
10,000 (100x100) association rules were evaluated by calculating their 𝑅𝑅, 2χ  and a values. The 
experiment results are provided in Table 6. As expected, the results show that indexes 
dramatically affect the overall performance of our SQL-based algorithm. The number of 
connections has less effect on the performance. However, if indexes are set properly, the time 
consumed by making a lot of connections are still relatively high (see the last two columns of 
Table 6). Note that a user of the system normally checks one drug-reaction pair each time, which 
takes a very small amount of time (comparable to 1 millisecond with indexes and one connection 
for each database). In addition, the data mining agent can be configured to automatically run the 
algorithm after every certain period of time (e.g., one month) after new data are entered into the 
database. Then, a query of a pair would be simply to check a table that contains the 𝑅𝑅, 2χ  and a 
values for each pair. 
Table 6: Execution time of the association mining algorithm under different experiment 
conditions 
 Experiment Conditions 
No Indexes, 




for Each Database 
With Indexes, 




for Each Database 
Execution 
Time (seconds) 7935 7793 45 7.2 
As indexes are so important for reducing the execution time of the algorithm, we decided to test 
how different index storage types affect the performance using the same dataset. The MySQL 
utilized in this study supports two index types: HASH and BTREE. Note that when a new index 
type is applied to the database, the first run of the program would take much longer time than the 
following runs since the computer needs time to build the indexes and store them into a new data 
structure. We examined the execution time for the first run of the program and the average time 
for the next 10 runs with each index type. The results are presented in Table 7. The table 
indicates no significant difference of the execution time when using different index types. 
Table 7: Execution time of the association mining algorithm under different index storage types 
 
Index Storage Type 
HASH BTREE 
Execution Time for the 
First Run 34.1 34.8 
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Average Execution Time 
for the Next 10 Runs 7.3 7.2 
As each health organization may have a lot of patient data, the scalability of our SQL-based 
association mining algorithm is very important. We tested the scalability of Algorithm 1 in terms 
of the size of the data. We started with 100,000 patient cases, and then added additional 100,000 
cases each time the program was executed. The execution time against the number of patient 
cases was plotted as shown in Figure 3. One can see that our algorithm is scalable in terms of the 
size of the patient data. 
 
Figure 3: Scalability of the association mining algorithm in terms of the number of patient cases 
Discussion 
The proposed rule-based algorithm can be used to assess the degree of association between a 
drug and a potential ADR within a single patient case. However, even if the causality category 
assigned by the algorithm is “likely” or “definite”, that may not represent real causal association 
due to the complexity of the ADR problem. For example, a syndrome or an adverse effect may 
be caused by various other conditions (e.g., underlying diseases), even though the syndrome and 
the associated drug satisfy one or more rules in the algorithm given the patient data. In addition, 
a reaction of a drug may indirectly cause an adverse effect. In this sense, the rule-based 
algorithm should not be used for the purpose of accurately establishing the causal relationship 
between a drug and an ADR. Instead, it is an assistant tool that would encourage healthcare 
professionals to file spontaneous reports of suspected ADRs. 
The statistical analysis results given by the proposed data mining method provide another 
perspective for healthcare professionals to examine the drug-ADR pair of interest. Please note 
that some false ADR signals may be generated due to the nature of the ADR problem and the 
complication of medical data. First, ADRs normally occur very infrequently. Thus, the adverse 
effects caused by ADRs can be hidden by other high frequency symptoms. Second, frequently 
prescribed drugs are often associated with common symptoms by coincidence. These data noises 
could reduce the effectiveness of any association mining methods. Third, the electronic data may 
be incomplete and has potential bias and even errors [31]. For example, some potential adverse 
effects may not be recorded in a health database if the results caused by drug reactions are not 
serious. Please note that, in post-marketing surveillance, data mining is primarily used to 
generate ADR signals that will be subject to further analysis. To establish true causal 
associations, other labor-intensive approaches such as epidemiology study, case review, and 
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interpretation by drug safety professionals experienced in the nuances of pharmacoepidemiology 
and clinical medicine are often used [32]. 
The rule-based algorithm and the data mining method are complementary to each other. While 
the former examines the causal association between a drug and an ADR based on the data within 
a single patient case, the latter assesses the association based on all the data from a statistical 
perspective. They can be used together to assist healthcare professionals to decide whether a 
drug-ADR pair has causal association. Note that even if a signal generated by the data mining 
method represents true causal association, the relevant ADR is not necessary to occur on a 
patient who has taken the drug of interest due to the variation of human bodies. Hence, the rule-
based algorithm has to be checked when a healthcare professional decides whether a spontaneous 
report should be filed for a particular patient case. In addition, when there exist few patient cases 
in which the drug and ADR coexist, the data mining method become less reliable. 
The auto-filling feature of the proposed multi-agent system can improve the quality and 
consistency of the submitted ADR reports. By looking at FDA’s spontaneous reports, we found 
that there existed a lot of typo-errors and some information such as age, gender, drug dose, and 
so forth are often missing. Since our system can automatically fill out the major portion of the 
reporting form, these issues can be effectively avoided. 
Our system can also be easily adapted to improve other drug safety-related practices in a health 
organization. For example, it could help physicians make more appropriate choices in drug 
prescription and avoid preventable ADRs. It could also help make formulary decisions. To 
ensure quality and cost effectiveness of patient care, it has been a common practice in the past 
decades that healthcare organizations (e.g., hospitals) establish their formularies [33]. The basic 
premise is that within a given drug class, there is significant overlap and duplication relative to 
efficacy and safety. A single drug that is representative of a therapeutic class can meet the needs 
of the vast majority of patients. Selecting only one drug streamlines inventory, purchasing and 
maintenance of databases, diminishes the likelihood of medication errors, and creates a 
competitive environment for pricing. A major barrier to effective formulary decision making is 
the lack of sufficient published data on the safety of drugs, particularly recently marketed drugs. 
Our system could provide continuous, active surveillance and timely identification of potential 
safety issues following the introduction of a new drug to a formulary. Such a system could lead 
to safer drug use policy, more cost-effective formulary decisions, better healthcare, and earlier 
detection of ADRs. 
Conclusion 
We have developed an agent-based ADR reporting system that can potentially improve the 
spontaneous reporting rate by providing decision-making assistance and automatically feeding 
most data into the reporting form. This system will be practically tested in the Frontier 
Behavioral Health in Spokane, Washington. 
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